248 related articles for article (PubMed ID: 22666895)
1. Chemotherapy treatment options and policies.
Breshears Wheeler J; Hanson K
NCSL Legisbrief; 2012 May; 20(19):1-2. PubMed ID: 22666895
[No Abstract] [Full Text] [Related]
2. Pharmaceuticals and medical devices: Medicare Part D. End-of-year issue brief.
Chaps NA
Issue Brief Health Policy Track Serv; 2008 Jan; ():1-23. PubMed ID: 18345558
[No Abstract] [Full Text] [Related]
3. Pharmaceuticals issue brief: managed care drug formularies: year end report-2003.
MacEachern L
Issue Brief Health Policy Track Serv; 2003 Dec; ():1-8. PubMed ID: 14969259
[TBL] [Abstract][Full Text] [Related]
4. Pharmaceuticals and medical devices: Medicare Part D. End-of-year issue brief.
Chaps NA
Issue Brief Health Policy Track Serv; 2009 Jan; ():1-26. PubMed ID: 19301435
[No Abstract] [Full Text] [Related]
5. The new Medicare bill: far-reaching effects on cancer treatment.
Bailes JS; Coleman T
Clin Adv Hematol Oncol; 2004 May; 2(5):292-4. PubMed ID: 16163195
[TBL] [Abstract][Full Text] [Related]
6. Oral/infusion cancer drug parity begins to raise health plan costs.
Carroll J
Manag Care; 2012 Jan; 21(1):7-8. PubMed ID: 22334937
[No Abstract] [Full Text] [Related]
7. Pharmaceuticals issue brief: pharmaceutical assistance programs: year end report--2004.
Seay M
Issue Brief Health Policy Track Serv; 2004 Dec; ():1-26. PubMed ID: 15724309
[No Abstract] [Full Text] [Related]
8. Pharmaceuticals and medical devices: Medicare Part D.
; Steiner DJ
Issue Brief Health Policy Track Serv; 2012 Jan; ():1-37. PubMed ID: 22403844
[No Abstract] [Full Text] [Related]
9. Prescription drug costs easier to swallow.
State Legis; 2010 Apr; 36(4):10. PubMed ID: 20397320
[No Abstract] [Full Text] [Related]
10. Drug Pricing Trends for Orally Administered Anticancer Medications Reimbursed by Commercial Health Plans, 2000-2014.
Dusetzina SB
JAMA Oncol; 2016 Jul; 2(7):960-1. PubMed ID: 27123993
[No Abstract] [Full Text] [Related]
11. Pharmaceuticals and medical devices: Medicare Part D. End-of-year issue brief.
Chaps NA
Issue Brief Health Policy Track Serv; 2010 Jan; ():1-19. PubMed ID: 20213917
[No Abstract] [Full Text] [Related]
12. The new Medicare prescription-drug legislation.
Altman DE
N Engl J Med; 2004 Jan; 350(1):9-10. PubMed ID: 14702422
[No Abstract] [Full Text] [Related]
13. Health insurance oversight issue brief: mandated benefits: off-label drug coverage requirements: year end report--2004.
Plaza CI
Issue Brief Health Policy Track Serv; 2004 Dec; ():1-9. PubMed ID: 15726733
[No Abstract] [Full Text] [Related]
14. Pharmaceuticals: pharmacy benefit management regulations--2005. End of Year Issue Brief.
Seay M
Issue Brief Health Policy Track Serv; 2005 Dec; ():1-9. PubMed ID: 16710927
[No Abstract] [Full Text] [Related]
15. Affordable prescription drugs--state and federal action.
Ohio Nurses Rev; 2003 Aug; 78(7):4. PubMed ID: 15134064
[No Abstract] [Full Text] [Related]
16. Pharmacy Plus: the perfect cure?
Cauchi R
State Legis; 2003 Feb; 29(2):20-1. PubMed ID: 12577977
[TBL] [Abstract][Full Text] [Related]
17. Pharmacoeconomic and clinical outcomes in oncology using oral chemotherapy.
Navarro RP; Morrow T; Baran R
Manag Care Interface; 2002 Jul; 15(7):55-62. PubMed ID: 12143298
[TBL] [Abstract][Full Text] [Related]
18. State regulation of private health insurance: prescription drug benefits, experimental treatments, and consumer protection.
Bolin JN; Buchanan RJ; Smith SR
Am J Manag Care; 2002 Nov; 8(11):977-85. PubMed ID: 12437312
[TBL] [Abstract][Full Text] [Related]
19. Finance issue brief: mandated benefits: off-label drug coverage requirements: year end report-2003.
Plaza CI
Issue Brief Health Policy Track Serv; 2003 Dec; ():1-9. PubMed ID: 14870745
[No Abstract] [Full Text] [Related]
20. Cancer Care Under the Biden Administration.
Dusetzina SB
JAMA; 2021 Feb; 325(6):527-528. PubMed ID: 33560329
[No Abstract] [Full Text] [Related]
[Next] [New Search]
